ATE403745T1 - Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis - Google Patents

Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis

Info

Publication number
ATE403745T1
ATE403745T1 AT99972008T AT99972008T ATE403745T1 AT E403745 T1 ATE403745 T1 AT E403745T1 AT 99972008 T AT99972008 T AT 99972008T AT 99972008 T AT99972008 T AT 99972008T AT E403745 T1 ATE403745 T1 AT E403745T1
Authority
AT
Austria
Prior art keywords
sepsis
drugs
development
determining susceptibility
treating
Prior art date
Application number
AT99972008T
Other languages
English (en)
Inventor
Giovine Francesco Di
Gordon Duff
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Application granted granted Critical
Publication of ATE403745T1 publication Critical patent/ATE403745T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99972008T 1998-10-30 1999-11-01 Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis ATE403745T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/183,850 US6251598B1 (en) 1998-10-30 1998-10-30 Methods for diagnosing sepsis

Publications (1)

Publication Number Publication Date
ATE403745T1 true ATE403745T1 (de) 2008-08-15

Family

ID=22674558

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972008T ATE403745T1 (de) 1998-10-30 1999-11-01 Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis

Country Status (10)

Country Link
US (2) US6251598B1 (de)
EP (1) EP1127168B1 (de)
JP (1) JP2002533096A (de)
AT (1) ATE403745T1 (de)
AU (1) AU779772B2 (de)
CA (1) CA2346960A1 (de)
DE (1) DE69939269D1 (de)
ES (1) ES2308861T3 (de)
IL (1) IL142438A0 (de)
WO (1) WO2000037679A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US20050032077A1 (en) * 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
AU2001263373A1 (en) * 2000-09-20 2002-04-02 Genaissance Pharmaceuticals, Inc. Haplotypes of the il1b gene
US20040028651A1 (en) * 2001-03-29 2004-02-12 Karrupiah Muthumani Composition and methods of using hiv vpr
AU2002362753B9 (en) * 2001-10-05 2008-05-15 The Trustees Of The University Of Pennsylvania Compositions for and methods of treating and preventing sirs/sepsis
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
WO2003044176A2 (en) * 2001-11-19 2003-05-30 Interleukin Genetics, Inc. Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
WO2004044555A2 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
BR0316231A (pt) * 2002-11-12 2005-10-04 Becton Dickinson Co Métodos para determinar o estado de sepsia para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo e para isolar um biomarcador, perfil biomarcador r kit
CA2505785A1 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
WO2005038427A2 (en) * 2003-06-05 2005-04-28 Medical Gene Center Ltd. Rapid identification of viruses of the upper respiratory tract infection including sars causing coronus viruses
PL1673472T3 (pl) * 2003-10-06 2011-07-29 Novartis Ag Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez leki
EP1723160A4 (de) * 2004-03-04 2008-04-23 Univ British Columbia Haplotypen des toll-like receptor 2 (tlr-2) als indikatoren für das resultat bei patienten
US20070281300A1 (en) * 2004-03-04 2007-12-06 James Russell Thrombomodulin (Thbd) Haplotypes Predict Outcome
US8034553B2 (en) * 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
US20060157647A1 (en) * 2005-01-18 2006-07-20 Becton, Dickinson And Company Multidimensional liquid chromatography/spectrometry
EP1851245B1 (de) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antikörper gegen interleukin-1-beta
CN101151536A (zh) 2005-03-30 2008-03-26 株式会社岛津制作所 反应容器中的不挥发性液体分注方法及反应容器处理装置
AU2006236588A1 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
WO2010070136A2 (en) * 2008-12-19 2010-06-24 Centre de Recherche Public de la Santé Novel caviidae allergens and uses thereof
US9913880B2 (en) 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock
WO2014210031A1 (en) 2013-06-25 2014-12-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Proteomic biomarkers of sepsis in elderly patients
AU2017207341A1 (en) 2016-01-12 2018-08-02 Interleukin Genetics, Inc. Methods for predicting response to treatment
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
US20220249660A1 (en) 2019-06-06 2022-08-11 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
ATE178094T1 (de) 1990-05-01 1999-04-15 Chiron Corp Interleukin-i antagonist und seine verwendung
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
DE4408890A1 (de) 1994-03-16 1995-09-21 Knoll Ag Verwendung von Il-1-Antagonisten als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
US5686246A (en) * 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5942390A (en) * 1996-01-12 1999-08-24 Cedars-Sinai Medical Center Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism
AU2213697A (en) 1996-03-18 1997-10-10 Medical Science Systems, Inc. A method for periodontal disease treatment
GB9621129D0 (en) 1996-10-10 1996-11-27 Duff Gordon W Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6210877B1 (en) 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
AU760856B2 (en) 1997-05-29 2003-05-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for chronic obstructive airway disease
GB9711040D0 (en) 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis

Also Published As

Publication number Publication date
ES2308861T3 (es) 2008-12-01
US20010034032A1 (en) 2001-10-25
WO2000037679A2 (en) 2000-06-29
IL142438A0 (en) 2002-03-10
DE69939269D1 (de) 2008-09-18
EP1127168B1 (de) 2008-08-06
EP1127168A2 (de) 2001-08-29
JP2002533096A (ja) 2002-10-08
US6251598B1 (en) 2001-06-26
US6551785B2 (en) 2003-04-22
AU3995600A (en) 2000-07-12
WO2000037679A3 (en) 2001-01-11
CA2346960A1 (en) 2000-06-29
AU779772B2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
ATE403745T1 (de) Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis
ATE376187T1 (de) Nachweis von erkrankungen der nieren und behandlung
DE69735295D1 (de) Verfahren zur Aufkonzentrierung von Antikörperlösungen
DE69739000D1 (de) Gerät und verfahren zur bestimmung der quelle eines lokalsignals
ATE188778T1 (de) Verfahren und verbindungen zur magnetorelaxometrischen detektion von analyten und deren verwendung
DE69430231D1 (de) Biosensor zum Messen der Alkoholkonzentration, Verfahren zur Herstellung des Biosensors, und den Biosensor benutzendes Betrunkenheitsmessgerät
DE69617581D1 (de) System und Verfahren zur Bestimmung des Verlaufs der Grundfrequenz
DD138921A5 (de) Verfahren und reagens zur bestimmung von alpha-amyl&se
DE69605590D1 (de) Verfahren zum Nachweis von Protein und Kit dafür
DE69936553D1 (de) Verfahren zur Konzentrationsmessung von NOx
DE69124511D1 (de) Verfahren für den nachweis und/oder die bestimmung von hormonen
DE69524919D1 (de) Verfahren und Vorrichtung zur Bestimmung der Konzentration von Gaskomponenten
AT360661B (de) Verfahren zur bestimmung von prothrombin und reagens zur durchfuehrung des verfahrens
DE69626311D1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE69934789D1 (de) Verfahren zur bestimmung der antibiotikasensitivität von bakterien
DE59814359D1 (de) Mikrostrukturierter biosensor, verwendung des biosensors und verfahren zur immobilisierung von biokatalysatoren
ATE506075T1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE69930725D1 (de) Verfahren und kits zur behandlung von vulvovaginalen candidosen mit mikonazolnitrat
NO973823D0 (no) Påvisning av antistoffproduksjon
DE69422890T2 (de) Verfahren und Vorrichtung zur Bestimmung der Konzentration von Verunreinigungselementen
DE69838872D1 (de) Verfahren und testkit zum nachweis von heroin
DE69104438T2 (de) Verfahren zur bestimmung von glukose-6-phosphat und zusammensetzung dafür.
DE3783840D1 (de) Verfahren zur bestimmung von plasma-protein und testsatz dafuer.
ATE458813T1 (de) Verfahren zur bestimmung von ctp11 sowie zur bestimmung des metastatischen potentials einer tumor probe
DE59504158D1 (de) Verwendung sulfierter substanzen zur fettung von leder

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties